

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

NCT05898646

Status	RECRUITING
Phase	Phase 2
Sponsor	Mayo Clinic
Enrollment	96 participants

Key Eligibility Criteria

Inclusion (21)

- Age \geq 18 years
 - Histological confirmation of AL amyloidosis with adequate typing (mass spectrometry, immunohistochemistry, immunofluorescence, immunogold)
 - AL amyloidosis with organ disease requiring therapy
 - NOTE: Disease requiring therapy is referred to the time of diagnosis. There are no limitations in baseline measurable disease parameters
 - Patients must have monoclonal protein studies (serum free light chain assay, serum immunofixation or serum MASS-FIX) obtained at time of diagnosis before induction therapy initiated and available for review to be enrolled.
- ... and 16 more (see full listing online)

Exclusion (22)

- Any of the following because this study involves an agent that has possible genotoxic, mutagenic and teratogenic effects:
 - Pregnant persons
 - Nursing persons
 - Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception
 - Received $>$ 1 cycle of daratumumab maintenance after end of induction therapy and prior to registration
- ... and 17 more (see full listing online)

Locations (2 total)

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States